New drug combo tested in Tough-to-Treat lung cancer
NCT ID NCT03575793
Summary
This study tested a combination of three drugs—nivolumab, ipilimumab, and plinabulin—for patients whose small cell lung cancer had returned after initial chemotherapy. The goal was to find a safe dose and see if the combination could help control the cancer. The trial involved 39 adults and was completed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Erlanger Health System
Chattanooga, Tennessee, 37403, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.